Multi-institutional validation of the predictive value of ki-67 labeling index in patients with urinary bladder cancer

Journal of the National Cancer Institute

Volumn 101, Issue 2, 2009, Pages 114-119

  Margulis, Vitaly ^a   Lotan, Yair ^b   Karakiewicz, Pierre I ^c   Fradet, Yves ^d   Ashfaq, Raheela ^b   Capitanio, Umberto ^c,e   Montorsi, Francesco ^e   Bastian, Patrick J ^f,g   Nielsen, Matthew E ^f,h   Müller, Stefan C ^f   Rigaud, Jérôme ^d   Heukamp, Lukas C ^f,h   Netto, George ^h   Lerner, Seth P ⁱ   Sagalowsky, Arthur I ^b   Shariat, Shahrokh F ^b,j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; TUMOR MARKER;

AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MULTIVARIATE ANALYSIS; ONCOLOGY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME; VALIDATION STUDY; ANALYSIS OF VARIANCE; BLADDER TUMOR; CARCINOMA; CLINICAL TRIAL; EPIDEMIOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; UROTHELIUM;

ANALYSIS OF VARIANCE; CARCINOMA; CYSTECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; LYMPH NODE EXCISION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SELECTION BIAS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 59049085842     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn451     Document Type: Article

References (23)

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
2. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 pt 1):2414-2422; discussion 2422.
3. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2):315-325.
4. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168(4):357-363.
5. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369-7373.
6. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95(9):634-635.
7. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-519.
8. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543-2546.
9. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
10. Greene FL. American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
11. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145(3):459-464; discussion 464-467.
12. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992;148(2 pt 1):302-306; discussion 306-307.
13. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155(2):495-499; discussion 499-500.
14. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927-1934.
15. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178(2):451-454.
16. Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer [published online ahead of print March 5, 2008. Review]. BJU Int. 2008;102(1):15-22.
17. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6 suppl. 1):64-74.
18. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004;10(12 pt 1):4118-4124.
19. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 1997;80(8):1472-1481.
20. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of Ki-67 expression in transitional cell bladder carcinoma after radical cystectomy. Pathol Res Pract. 1997;193(8):551-556.
21. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048-8056.
22. Morinaga S, Ishiwa N, Noguchi Y, et al. Growth index, assessed with Ki-67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma. J Surg Oncol. 2005;92(4):331-336.
23. Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008;100(3):207-212.